The interest in PuraStat mucosal healing has grown quickly as gastroenterologists look for better ways to reduce delayed bleeding and improve recovery after advanced endoscopic procedures. Complex resections like EMR and ESD have changed the way early gastrointestinal lesions are treated. However, they also create large mucosal defects that can take time to heal.

Slow healing often increases the risk of bleeding, infection and patient discomfort. Because these issues affect both clinical outcomes and healthcare costs, the search for a reliable healing support tool has become important.

A new preclinical study in a porcine model evaluated PuraStat as a potential mucosal healing enhancer. The results are promising, and they support what early human data already suggest. Although the study focuses on animals, the design and outcomes make the findings valuable for clinicians who want to understand how self-assembling peptide hydrogels may improve recovery after EMR and ESD.

NX210c is emerging as one of the more scientifically grounded preclinical candidates in spinal cord injury research. Spinal cord injury, often referred to as SCI, remains a devastating neurological condition that affects hundreds of thousands of people worldwide every year.

Patients frequently experience permanent motor, sensory, and autonomic deficits below the site of injury. Despite decades of intensive research, pharmacological therapies that reliably restore motor function after SCI remain limited, and most treatment strategies still focus on surgical intervention, acute stabilization, and long-term rehabilitation rather than true neurological repair.

Against this backdrop, NX210c has attracted attention for its multi-dimensional effects in animal models of SCI. Derived from thrombospondin-related biology, NX210c has demonstrated improvements in motor function, tissue preservation, and neuronal signaling in preclinical studies.